TY  - JOUR
AU  - Almeida, Antonio M
AU  - Prebet, Thomas
AU  - Itzykson, Raphael
AU  - Ramos, Fernando
AU  - Al-Ali, Haifa
AU  - Shammo, Jamile
AU  - Pinto, Ricardo
AU  - Maurillo, Luca
AU  - Wetzel, Jaime
AU  - Musto, Pellegrino
AU  - Van De Loosdrecht, Arjan A
AU  - Costa, Maria Joao
AU  - Esteves, Susana
AU  - Burgstaller, Sonja
AU  - Stauder, Reinhard
AU  - Autzinger, Eva M
AU  - Lang, Alois
AU  - Krippl, Peter
AU  - Geissler, Dietmar
AU  - Falantes, Jose Francisco
AU  - Pedro, Carmen
AU  - Bargay, Joan
AU  - Deben, Guillermo
AU  - Garrido, Ana
AU  - Bonanad, Santiago
AU  - Diez-Campelo, Maria
AU  - Thepot, Sylvain
AU  - Ades, Lionel
AU  - Sperr, Wolfgang R
AU  - Valent, Peter
AU  - Fenaux, Pierre
AU  - Sekeres, Mikkael A
AU  - Greil, Richard
AU  - Pleyer, Lisa
PY  - 2017
DO  - 10.3390/ijms18040837
UR  - http://hdl.handle.net/10668/11108
T2  - International journal of molecular sciences
AB  - Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with...
LA  - en
KW  - acute erythroleukemia
KW  - azacitidine
KW  - decitabine
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Azacitidine
KW  - Biomarkers
KW  - Bone Marrow
KW  - Cytogenetic Analysis
KW  - Decitabine
KW  - Female
KW  - Humans
KW  - Leukemia, Erythroblastic, Acute
KW  - Male
KW  - Middle Aged
KW  - Proportional Hazards Models
KW  - Retrospective Studies
KW  - Survival Analysis
KW  - Treatment Outcome
TI  - Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
TY  - research article
VL  - 18
ER  -